Lynx1 Capital Management Lp
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$632.7M
Q ending 2026-03-31
Prior quarter
$494.0M
Q ending 2025-12-31
Change
+28.1% QoQ · +126.6% YoY
Positions
23
reported holdings
Largest positions
All 23 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Stoke Therapeutics Inc | STOK | Shares | $155.1M | 4.8M |
| Gh Research Plc | Shares | $151.3M | 10.8M | |
| Cullinan Therapeutics Inc | CGEM | Shares | $127.4M | 9.0M |
| Agios Pharmaceuticals Inc | AGIO | Shares | $88.3M | 2.6M |
| Denali Therapeutics Inc | DNLI | Shares | $36.1M | 1.9M |
| C4 Therapeutics Inc | CCCC | Shares | $18.4M | 7.0M |
| Korro Bio Inc | KRRO | Shares | $17.4M | 1.5M |
| Tscan Therapeutics Inc | TCRX | Shares | $8.1M | 8.0M |
| Xencor Inc | XNCR | Shares | $6.5M | 536K |
| Precision Biosciences Inc | DTIL | Shares | $5.4M | 985K |
| Passage Bio Inc | PASG | Shares | $4.9M | 624K |
| Neuphoria Therapeutics Inc | NEUP | Shares | $3.6M | 875K |
| Entrada Therapeutics Inc | TRDA | Shares | $2.7M | 212K |
| Cg Oncology Inc | CGON | Shares | $2.1M | 32K |
| Immatics N.V | Shares | $2.1M | 217K | |
| Design Therapeutics Inc | DSGN | Shares | $1.3M | 120K |
| Vyne Therapeutics Inc | VYNE | Shares | $973K | 1.6M |
| Werewolf Therapeutics Inc | HOWL | Shares | $548K | 658K |
| Ibio Inc | IBIO | Shares | $129K | 68K |
| Bolt Biotherapeutics Inc | BOLT | Shares | $124K | 31K |
| Proqr Thrapeutics N V | Shares | $111K | 68K | |
| Absci Corporation | ABSI | Shares | $64K | 21K |
| Traws Pharma Inc | TRAW | Shares | $28K | 15K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.